Efficacy News and Research

RSS
WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

WHO highlights threat of antimalarial drug resistance in Greater Mekong subregion

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Transformative technologies highlighted in current issue of Technology and Innovation

Transformative technologies highlighted in current issue of Technology and Innovation

Research project to identify mechanisms underlying effects of cancer drug interferon-α

Research project to identify mechanisms underlying effects of cancer drug interferon-α

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage to heart and lungs can be limited by using CVD drug

Many parents give young kids medicines that they should not use

Many parents give young kids medicines that they should not use

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

New collaboration to expand vaccine approaches for melanoma

New collaboration to expand vaccine approaches for melanoma

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.